Biological Therapies for Cancer: Technologies and Global Markets
The global market for biologic cancer treatment totaled about $51.2 billion in 2014 and is expected to reach $66.4 billion in 2019, registering a compound annual growth rate (CAGR) of 5.4% for the period 2014-2019.
- An overview of the global markets and technologies for biological therapies for cancer
- Analyses of global market trends, with data from 2013 and 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Detailed analyses of products in the market, market structure and competitive environments, cancer markets in newly emerging therapeutics, and analysis of biosimilars and their impact on the market.
- Details concerning the strengths, weaknesses, opportunities, and threats facing various cancer biotherapeutics already on the market.
- A look at major issues involved in the research and development (R&D) of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials.
- Comprehensive profiles of major players in the cancer biotherapeutics field.
This report provides an update on BIO048B Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2019. It discusses important biologics, market share by cancer type, products on the market, market share by company, statistical information for cancer types prevalent globally, with special emphasis on the U.S. market. It also includes current issues and trends affecting the industry, costs and factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.
The market and sales data for various years gives strong support for the research and development (R&D) program and the move toward biologic treatment for cancer, as well as within biologic toward human monoclonal antibodies, vaccines and interferons. The biologic drug classes discussed in this report with special focus on cancer treatment are:
- Monoclonal antibodies.
- Colony stimulating factors.
- Interleukins and interferons.
The following approaches to cancer therapeutics are excluded in the report:
- Alkylating agents.
- Cytotoxic agents.
- Plant derivatives and hormone therapy corticosteroids.
- Hormone antagonists/antagonists aromatase inhibitors.
- Radiation therapy.
- Adjunctive therapy.
Biological therapies for treatment of other diseases will not be addressed in this report.
The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including:
- Treatment trends and sales patterns across major cancer indications for Japan, Europe E.U.5 nations (i.e., France, Germany, Italy, Spain, the U.K.), the U.S. and the rest of the world (ROW).
- Market performance of major pharmaceutical companies.
- Forecast sales of leading products across major indications to 2019.
- Biosimilars and their impact on currently marketed cancer biotherapeutics.
Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has more than 10 years of pre-clinical, alliance management, discovery and technology development, and marketing experience. Her primary focus areas include oncology and cardiovascular diseases, along with expertise in molecular and cell biology and complex cell-based biological assays, ranging from drug discovery, in vitro and in vivo screening, in vivo model development and pharmacokinetics. She also has experience working with early start-up companies.